Zogenix — Investor Presentation (June 2014)
31 slides from Zogenix's investor presentation, Jun 4, 2014
Slide 1: Overview
Exhibit 99.1 Overview June 2014
Slide 2: Forward Looking Statement
2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assumin
Slide 3: The Zogenix Opportunity
3 The Zogenix Opportunity UNIQUE MODEL Combining Medicine and Technology to Provide Differentiated Products That Meet Medical Needs PROVEN EXECUTION 2 FDA Approvals, Successful Commercial Product, Validated DosePro Platform, Strong Pipeline SIGNIFICANT MARKET OPPORTUNITY 1st to Market in Large Oppor
Slide 4: Unique Model: Combining Medicine and Technology
4 Unique Model: Combining Medicine and Technology Medicine Technology Oral, 12-Hour Extended Release Once Monthly Subcutaneous Injection DosePro® Needle-Free Delivery Platform COMMERCIALIZING and DEVELOPING Innovative Products CHRONIC PAIN ANTIPSYCHOTIC INTERNAL/EXTERNAL Hydrocodone Without Acetamin
Slide 5: 1st to Develop/Market Innovative Products
5 1st to Develop/Market Oral, 12-Hour Extended Release Hydrocodone without Acetaminophen 1 st Subcutaneous Once-Monthly Antipsychotic 1 st DosePro Needle Free Product For Acute Migraines And Cluster Headaches 1 st CHRONIC PAIN ANTIPSYCHOTIC CNS $16B Market US Market Unpartnered Launch March 2014 $29
Slide 6: SUMAVEL DosePro Transaction Well Positioned to Optimize Commercial Focus
6 SUMAVEL DosePro® Transaction Well Positioned to Optimize Our Commercial Focus on Pain Management • Better Call Point Fit • Significant Resources for Education and Marketing • Transfer of New Drug Application • Worldwide Product Rights • Purchase of Finished Goods Inventory • Strengthens Balance Sh
Slide 7: Strong Pipeline
7 Strong Pipeline PRODUCT/ PROGRAM Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Commercial Status Zohydro ER ER Hydrocodone Capsules For Chronic Pain Approved October 25 2013 Launched March 3rd 2014 2 AD Formulations N/A N/A • Targeting Late 2016 RELDAY Monthly SQ Risperidone for Schizophrenia • MD PK S
Slide 8: Oral, Extended Release Hydrocodone Acetaminophen-Free Product
8 Oral, Extended Release Hydrocodone Acetaminophen-Free Hydrocodone Product 1 st 1 st Oral, Extended Release Hydrocodone Acetaminophen-Free Hydrocodone Product FDA Approved October 2013 Launched March 2014
Slide 9: Zohydro ER Progress
9 Zohydro ER Progress MOMENTUM EDUCATION/ LEGAL • 1,141 Prescriptions in First Quarter 2014 • 6,423 prescriptions from launch through May 23, 2014 • >80%, of Prescriptions for Zohydro ER Are for the 30 mg Strength or Less, as Anticipated • Engaging Local, State and National Officials to Educate on M
Slide 10: Zohydro ER
10 Zohydro ER • Multiple Strengths (10-50 mg) • DEA Schedule II Product with Class-Wide REMS • Voluntary Initiatives to Support Appropriate Use • 2 Orange Book Patents with Expiry in Nov 2019 • Orange Book NP Exclusivity Through Oct 2016 • Abuse Deterrent (AD) Formulations in Development that May Al
Slide 11: Ideal Profile for Chronic Pain Treatment
11 Ideal Profile for Chronic Pain Treatment CONSISTENT 12 Hour Profile to Prevent Breakthrough Pain LOWER Maximum Concentration LESS Peak to Trough Variation Zohydro ER vs. Vicodin Mean Plasma Concentration ng/ml Zohydro ER 20 mg T0 Vicodin 10 mg T0 + T6
Slide 12: Responder Graph and Indication Details
12 Responder Graph and Indication Details p < 0.001 p < 0.001 68% 31% Zohydro ER is an Opioid Agonist, Extended-Release Oral Formulation of Hydrocodone Without Acetaminophen, for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment and for Which Alterna
Slide 13: Lower Liver Toxicity
13 Lower Liver Toxicity 1. Larson AM et al. Acetaminophen-Induced Acute Liver Failure: Results a United States Multicenter, Prospective Study. HEPATOLOGY 2005;42:1364-1372 2. Michna, E, Duh, MS, Korves, C, Dahl, JL. Removal of opioid/acetaminophen comvination prescription pain medications: assessing
Slide 14: The Market Need for Extended Release (ER) Hydrocodone
14 The Market Need for Extended Release (ER) Hydrocodone 13 Million ER Opioid TRx Annually 5.0M 6.6M 1.0M 0.2M ER Products Oxycontin Aviza, Kadian, Embeda, MS Contin+ Generic ERs Opana ER (Including Generics) Exalgo ER Sales $2.6B $1.4B $528M $238M 1st ER Hydrocodone Source: SHS Source ® TRx and ret
Slide 15: The Medical Need
The Medical Need 5% Take It for Chronic Pain >90 Days > 20mg HC/d ¹ 2.4 Million Patients 47 Million * Patients Take IR HC/APAP Meeting the Need in Opioid Rotation * FDA analysis of IMS Health Total Patient Tracker data for 2011 (presented at Zohydro ER Advisory Committee, December 2012) 1 Proportion
Slide 16: Zohydro ER Illustrative 5% Market Opportunity
16 Zohydro ER Illustrative 5% Market Opportunity Approximately $240 Million Gross Revenue 2.4 Million Patients 5% Penetration (120,000 Patients) WAC Price per Day of Therapy: $8.30 Days per Month of Therapy: # of TRx per Year:
Slide 17: Systematic Approach to Responsible Commercialization
17 Systematic Approach to Responsible Commercialization EDUCATION MARKETING SALES MONITORING STORAGE • Broad, Integrated Educational Resources for Patients, Physicians and Pharmacists EDUCATION • Commercial Activity Focused On Selected Physicians MARKETING • Certification of Zogenix Territory Repres
Slide 18: Multiple Educational Resources for Patients, Prescribers, and Pharmacists
19 Multiple Educational Resources for Patients, Prescribers, and Pharmacists 18 Patient Toolkit Education and Safe Storage Offers Conversion Guide HCP Kit Healthcare and Provider Websites
Slide 19: Successful Execution: Zohydro ER
Successful Execution: Zohydro ER 20,000 60% 19 Targeting a Significant Footprint High Decile ER/LA Opioid Prescribers (Top 6 Deciles) of ER Opioid Market FOCUS COMMITMENT COMPLIANCE CONTROL Responsibly Building Adoption for Long-Term Success Commercial Organization of 190 Employees
Slide 20: Committed to Developing Abuse Deterrent Formulations
Modification of Existing SODAS Formulation with Alkermes Development of Novel Tablet Formulation with Altus Committed to Developing Abuse Deterrent (AD) Formulations 20 • First Step in AD Zohydro ER • Addition of Inert Beads That Form a Viscous Gel When Crushed and Dissolved in Aqueous Solvents • In
Slide 21: Once-Monthly Risperidone Subcutaneous Injection
21 Once-Monthly Risperidone With A Unique PK Profile, Available as a Subcutaneous Injection for Treatment of Schizophrenia 1 st Phase 1 Proof of Concept Established
Slide 22: Long Acting Injections: A Highly Attractive Market
22 Long Acting Injections (LAIs): A Highly Attractive Market Further Clinical Evidence of Earlier LAI Usage Will Likely Drive Additional Upside • Highly Concentrated U.S. Market with 11,000 Psychiatrists Prescribing Long- Acting Injectable Antipsychotics • Growing U.S. and EU Market for LAI Products
Slide 23: Relday Surpasses Current LAI Atypical Antipsychotics
23 Relday Surpasses Current LAI Atypical Antipsychotics (AA) on Multiple Attributes KEY ATTRIBUTES FROM PHYSICIAN RESEARCH RISPERDAL CONSTA (RISPERIDONE) INVEGA SUSTENNA (PALIPERIDONE) ZYPREXA RELPREVV (OLANZAPINE) ABILIFY MAINTENA (ARIPIPRAZOLE) RELDAY (RISPERIDONE) Relday Profile Delivers on Key F
Slide 24: Relday: A Differentiated Product Profile vs. Available LAIs
24 Relday: A Differentiated Product Profile vs. Available LAIs Positive Physician Reaction Higher Relative Rating 7 POINT SCALE: 1 = “WORST” AND 7 = “BEST” Relative Rating of Clinical and Product Merit PARTICIPANT RATING OF RELDAY PROFILE Initial Reaction to Relday RELDAY 4.5 5.7 5.1 Risperdal® CONS
Slide 25: Relday Clinical Program Status
25 Relday Clinical Program Status PROOF OF CONCEPT • Established in the First IND Study • Subjects with Schizophrenia (n=40) • Pharmacokinetics (PK) – Therapeutic Levels within 8 hours of Dosing – First Day Levels Consistent with Comparable Oral Dose – Duration Consistent with Once-monthly Dosing –
Slide 26: Relday Clinical Study Design
26 Relday Clinical Study Design OVERVIEW INJECTIONS TIMING • Starts in Q4 2014, ends Q3 2015 • Initiate Multiple-Dose PK and Safety Study (H2 2014) • ROW Partnering With Data (H2 2015) • End of Phase II Meeting (Q3/Q4 2015) • Begin Phase III Trial (H1 2016) NEXT STEPS (Target Dates) • Relday Patient
Slide 27: Financial Highlights
27 Financial Highlights Q1 2014 Net Product Revenue (Unaudited Sumavel DosePro/service revenue~$7.4m, Zohydro $286k) $7.7M Market Capitalization (5-16-14 ~139,309,000 Shares) $290M Cash Balance (1) (Q1 2014 proforma for sale of Sumavel DosePro to Endo) ~$100M Debt/Royalty (5-16-2014) $0M Common Stoc
Slide 28: 2014 Financial Guidance
28 2014 Financial Guidance Zohydro ER Revenue No Guidance in Launch Year Revenue for Manufacturing and Supply of Sumavel DosePro for Endo Low Single Digit Markup to Costs Which Will Be Recorded as a Component of Cost of Goods Sold Zohydro ER Gross Margin Approximately 85% of Net Zohydro ER Revenue R
Slide 29: Experienced Management Team
29 Experienced Management Team INDUSTRY EXPERIENCE INDUSTRY EXPERIENCE Roger Hawley* Chief Executive Officer Glaxo, GSK, Elan, InterMune Stephen Farr, Ph.D.* President Aradigm, Cardiff University Ann Rhoads Chief Financial Officer Premier, Sprout, DLJ, Bain & Co, Merrill Lynch R. Scott Shively Chief
Slide 30: Zogenix: Where Medicine Meets Technology
30 Zogenix: Where Medicine Meets Technology 1 st 1 st 1 st DEVELOPING and COMMERCIALIZING Innovative Products PROVEN EXECUTION RESPONSIBLE COMMERCIALIZATION UNIQUE MODEL INFRASTRUCTURE IN PLACE SIGNIFICANT MARKETS CHRONIC PAIN INTERNAL/EXTERNAL DosePro® Needle-Free Delivery Platform ANTIPSYCHOTIC
Slide 31: NSD NOHAGINDS
NSD NOHAGINDS LOGENIZ”? nacre ean